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Sperformed in three, high output, invasive cardiology centers in Poland, Bulgaria and
Spain. Patients with STEMI or Medina type 001 bifurcation lesions were excluded
from the registry. Provisional T-stenting was obligatory strategy. An angiographic
control was planned at 12 months in all patients. The primary end-point of the study is
the rate of death, myocardial infarction, in-stent thrombosis and target lesion revas-
cularization (TLR) after 12 months. At TCT2013 complete data will be available.
Results: Sixty patients with stable CAD or NST-ACS (78.3% vs 21.7%, respectively)
were included into this prospective, feasibility and safety assessment registry. The
average age of enrolled patients (71.7% males) was 66.411.3 yrs. There were 46
(76.7%) patients with hypertension, 23 (38.3%) with diabetes and 17 (28.3%) with
prior MI. Additionally, 28 patients (46.7%) underwent prior PCI, while 6 (10%)
patients had previous CABG. In 46.7% of cases the lesion was localized in LMS,
followed by 45% in LAD, 6.7% in LCx and 1.7% in RCA. According to Medina
classiﬁcation true bifurcations were present in 80%. All BiOSS stents were implanted
successfully (avg. pressure 14 atm). The mean nominal stent parameters were as
followed: 3.670.40mm x 2.980.39mm x 17.132.06mm. In 8 (13.3%) cases the
second stent was implanted within the side branch. In 5 cases (8.3%) asymptomatic
increase in TnI level was observed. At six months all patients were uneventful (out-of
hospital MACE rate 0%). Up to now control angiography after 12 months was per-
formed at 78% of patients and TLR was 6.4%.
Conclusions: Dedicated bifurcation sirolimus-eluting stent BiOSS LIM is a feasible
device with promising safety proﬁle and short-term clinical effectiveness. Long-term
data is pending.
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ABSORB EXTEND: An Interim Report on the 24-month Clinical Outcomes
from the First 250 Patients Enrolled
Robert J. Whitbourn1
1St. Vincent Hospital Melbourne, Melbourne, Australia
Background: The safety and performance of the Absorb Bioresorbable Vascular
Scaffold (Absorb BVS) (Abbott Vascular, Santa Clara, CA) has been previously
established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB
trial. Results out to 3 years have been presented in 100 patients from the ABSORB
Cohort B trial. At 36 months, the MACE rate was 10.0%, with no scaffold thrombosis
reported. ABSORB EXTEND was initiated as a global continued access study (outside
of the US) to expand experience with the Absorb BVS to different geographies. Addi-
tionally, patients were treated for longer coronary lesions than those in the ABSORB
trial using either longer scaffold lengths or planned overlap of the Absorb BVS.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study
that will enroll approximately 800 patients at up to 100 sites. Included are patients
with lesions  28 mm in length and reference vessel diameter of 2.0 - 3.8 mm (as
assessed by on-line QCA or IVUS). Treatment of a maximum of two de novo native
coronary artery lesions, each in a different epicardial vessel, is permitted.
Results: Interim 12-month data in the ﬁrst 250 ABSORB EXTEND study patients has
been previously presented. Patients included 35% with unstable angina, 29% with
prior MI and 25% with diabetes mellitus. The mean RVD was 2.58 mm and mean
lesion length was 11.7 mm. In these 250 patients, the MACE and TVF rates were
4.4% and 4.8% respectively. Long-term, 24-month follow-up data will be available for
these patients in October 2013 and will provide substantial data on the long-term
safety and performance of the Absorb BVS in a larger population of patients,
including those with planned overlapping and dual vessel treatment. Clinical
composites and component end points will be presented out to 24 months.
Conclusions: Long-term outcomes in approximately 250 patients at 24 months (the
largest patient cohort reported at this time point to date) from ABSORB EXTEND will
provide further insight into the safety and efﬁcacy of the Absorb BVS in patients with
longer lesions.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-32
First Report of the Four Year Clinical Results of The ABSORB Trial Evaluating
the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold in the
Treatment of Patients with de Novo Native Coronary Artery Lesions
Bernard Chevalier1
1ICPS, Massy, France
Background: The ABSORB Cohort A trial results demonstrated the safety of Absorb
BVS (Abbott Vascular, Santa Clara, CA, USA) in 30 patients with single de novo
native coronary artery lesions, with a low long-term MACE rate at 5 years (3.4%) and
no scaffold thrombosis. The ABSORB Cohort B trial, a continuation of that assess-
ment with a modiﬁed Absorb BVS, enrolled 101 patients at 12 sites in European and
Asia Paciﬁc regions in 2009.
Methods: The patients of the ABSORB Cohort B trial were divided into 2 groups,
Cohort B1 (45 patients) having imaging follow-up performed at 180 days and 2 years
and Cohort B2 (56 patients) having imaging follow-up performed at 1 and 3 years.
Key clinical endpoints include scaffold thrombosis, ischemia driven MACE (ID-
MACE) and its components at 30 days, 6, 9 and 18 months, and 1, 2, 3, 4 and 5 years.
Results: In the ABSORB Cohort B trial, the mean age was 62 years, 72% of patients
were male, 17% of patients were current tobacco users. Patients with diabetes: 17%,
hypertension: 66%, hypercholesterolemia: 85%, family history of CAD: 55%, stable
angina: 68%, of which15% having stable angina with CCS classiﬁcation of III or IV.
Patients with unstable angina: 15%, 2% with unstable angina of Braunwald Class III.
Lesion location was RCA (33%), LAD (43%), LCX (22%) and Ramus (1%), with
ACC/AHA lesion classiﬁcation of A for 1% of patients, B1 for 55%, B2 for 40% and
C for 4%. Clinical data up to 3 years showed an ID-MACE rate of 10.0% with no
events of scaffold thrombosis. Late loss at 3 years was 0.29  0.43mm. Quantitative
IVUS results revealed mean scaffold area and mean lumen area enlargement between
baseline and 3 years. The scaffold enlargement at 3 years was conﬁrmed by OCT.
Furthermore, OCT results conﬁrmed earlier pre-clinical data showing that the scaffold is
resorbed by 3 years. Overall, clinical outcomes from the ABSORB Cohort B Trial
(Groups 1 and 2) conﬁrm the performance and safety of the Absorb BVS out to 3 years.
Conclusions: Four-year data are currently being collected. The long-term 4-year
clinical results for Cohort B1 will be presented and will provide further insight into the
longer-term safety and efﬁcacy of the Absorb BVS.
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Bioresorbable Vascular Scaffold Use in Coronary Bifurcation Lesions
Toru Naganuma1, Azeem Latib1, Charis Costopoulos2, Filippo Figini2,
Charbel Naim1, Antonio Colombo3
1San Raffaele Scientiﬁc Institute, Milan, Italy, 2San Raffaele Scientiﬁc Institute, Milano,
Milano, 3EMO GVM Centro Cuore Columbus/San Raffaele Hospital, Milan, Italy
Background: The use of bioresorbable vascular scaffolds (BVS) in percutaneous coronary
intervention (PCI) has been restricted to simple lesions. Few centers are now utilizing BVS
in complex lesions including bifurcations. The aim of this study was to evaluate device
successandshort-termclinicaloutcomesofBVSimplanted inbifurcation lesionsatourcenters.
Methods: We evaluated patients treated with BVS for bifurcation lesions between
May 2012 and June 2013.
Results: A total of 49consecutivebifurcation lesions in 40patients (82.5%male,meanage
63.8 years) were identiﬁed. True bifurcations were observed in 63.3%. The main
bifurcation site was the left anterior descending artery/diagonal branch (73.5%). Intra-
coronary vascular ultrasound was used in 89.8%. Pre-dilation and post-dilation were per-
formed in all cases. Device success was achieved in 98.0%: a BVS was substituted for
a drug-eluting stent in one casewhere BVS could not be delivered to the side-branch across
themain-branchBVS.Details of double-stenting techniques includingﬁnal kissingballoon
inﬂation are shown in Table 1.On ﬁnal intracoronary imaging, therewas no overt evidence
of scaffold structural disruption. At median follow-up of 157 days, there was no death,
target vessel revascularization, follow-up myocardial infarction or stent thrombosis.
Conclusions: These preliminary results suggest that bifurcation lesions can possibly
be successfully treated with BVS. Intravascular ultrasound guidance and meticulous
technique may be important to optimize clinical outcome.acts/ORAL/Bioabsorbable Vascular Scaffolds B11
